Denali Therapeutics Inc (FRA:4DN)
€ 20.31 -0.18 (-0.88%) Market Cap: 2.85 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 54/100

Denali Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2023 / 03:30PM GMT
Release Date Price: €22.14 (-1.82%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst

Welcome to the Morgan Stanley Global Healthcare Conference. I'm Jeff Hung, one of the biotech analysts.

For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

For this session, we have Denali Therapeutics with Co-Founder and CEO, Ryan Watts. Welcome, Ryan.

Ryan J. Watts
Denali Therapeutics Inc. - Co-Founder, President, CEO & Director

Yes. Great to be here. Thank you, Jeff.

Jeff Hung
Morgan Stanley, Research Division - Equity Analyst

So for those who may not be familiar with Denali, can you provide a brief introduction?

Ryan J. Watts
Denali Therapeutics Inc. - Co-Founder, President, CEO & Director

Yes. So Denali founded now 8

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot